XETRA - Delayed Quote EUR

Bayer Aktiengesellschaft (BAYN.DE)

46.91 -0.09 (-0.19%)
As of 14:48:06 CEST. Market open.
Chart Range Bar
Loading chart for BAYN.DE
  • Previous close 47.00
  • Open 46.50
  • Bid 46.90 x 28400
  • Ask 46.94 x 2100
  • Day's range 46.10 - 47.60
  • 52-week range 24.81 - 49.78
  • Volume 4,365,030
  • Avg. Volume 2,869,233
  • Market cap (intra-day) 46.086B
  • Beta (5Y monthly) 0.85
  • PE ratio (TTM) --
  • EPS (TTM) -2.19
  • Earnings date (est.) 4 Aug 2026
  • Forward dividend & yield 0.11 (0.23%)
  • Ex-dividend date 27 Apr 2026
  • 1y target est 50.58

Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment offers nonprescription over-the-counter medicines for self-medication and self-care; nutritional supplements; allergy, cough, and cold; dermatology; pain and cardiovascular risk prevention; and digestive health products. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solutions, and pest and weed management products, as well as customer services for agriculture. It also engages in the breeding, propagation, and production/processing of seeds, including seed dressing. The company distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.

www.bayer.com

87,757

Full-time employees

31 December

Fiscal year ends

Healthcare

Sector

Drug Manufacturers - General

Industry

Performance overview

Trailing total returns as of 26/06/2026, which may include dividends or other distributions. Benchmark is DAX P (^GDAXI) .

YTD return

BAYN.DE
27.11%
DAX P (^GDAXI)
0.63%

1-year return

BAYN.DE
79.01%
DAX P (^GDAXI)
4.21%

3-year return

BAYN.DE
5.25%
DAX P (^GDAXI)
55.85%

5-year return

BAYN.DE
1.39%
DAX P (^GDAXI)
57.90%

Earnings trends

View more

Earnings per share

GAAP
Normalised
GAAP
Normalised
 

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue 13.4B
Earnings 2.66B

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

0
5bn
10bn
 

Analyst insights

View more

Analysts' price targets

40.00 Low
50.58 Average
46.91 Current
60.00 High
 

Analyst recommendations

  • Strong buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Statistics

View more

Valuation measures

As of 25/06/2026
  • Market cap

    46.17B

  • Enterprise value

    74.77B

  • Trailing P/E

    --

  • Forward P/E

    10.78

  • PEG ratio (5-yr expected)

    --

  • Price/sales (ttm)

    1.02

  • Price/book (mrq)

    1.60

  • Enterprise value/revenue

    1.65

  • Enterprise value/EBITDA

    23.65

Financial highlights

Profitability and income statement

  • Profit margin

    -4.76%

  • Return on assets (ttm)

    3.64%

  • Return on equity (ttm)

    -6.93%

  • Revenue (ttm)

    45.24B

  • Net income avi to common (ttm)

    -2.16B

  • Diluted EPS (ttm)

    -2.19

Balance sheet and cash flow

  • Total cash (mrq)

    6.66B

  • Total debt/equity (mrq)

    134.27%

  • Levered free cash flow (ttm)

    7.31B

Compare

Select to analyse similar companies using key performance metrics; select up to four stocks.

People also watch